Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)

被引：1

作者：

Barthelemy, P. ^{[1
]}

Thibault, C. ^{[2
]}

Voog, E. ^{[3
]}

Eymard, J-C. ^{[4
]}

Ravaud, A. ^{[5
]}

Flechon, A. ^{[6
]}

Jaillon, C. Abraham ^{[7
]}

Hilgers, W. ^{[8
]}

Le Moulec, S. ^{[9
]}

Chasseray, M. ^{[10
]}

Pouessel, D. ^{[11
]}

Amela, Y. E. ^{[12
]}

Lorgis, V. ^{[13
]}

Nicolas, E. ^{[14
]}

Kazan, E. ^{[15
,16
]}

Denechere, G. ^{[18
]}

Solbes, M-N. ^{[17
]}

Lambert, P. ^{[16
]}

Loriot, Y. ^{[18
]}

机构：

[1] Inst Cancerol Strasbourg Europe, Med Oncol, Strasbourg, France

[2] Univ Paris Cite, AP HP Ctr, Dept Med Oncol, Inst Canc Paris CARPEM, Paris, France

[3] ILC Grp, Clin Victor Hugo, Le Mans, France

[4] Inst Cancerol Jean Godinot, Dept Med Oncol, Reims, France

[5] Univ Bordeaux, Bordeaux Univ Hosp, Dept Med Oncol, Bordeaux, France

[6] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[7] Foch Hosp, Serv Oncol Med, Suresnes, France

[8] Avignon Provence Canc Inst, Dept Med Oncol, Avignon, France

[9] Clin Marzet, Med Oncol, Grp Radiotherapie & Doncol Pyrenees, Pau, France

[10] Clin Pasteur, Ctr Finisterien Radi Otherapie & Oncol, Brest, France

[11] Inst Claudius RegaudeIUCT Oncopole, Dept Med Oncol, Toulouse, France

[12] Hop Prive Bois, Ctr cancerol Bourgogne, Lille, France

[13] Inst Cancerol Bourgogne, Med Oncol ICB, Dijon, France

[14] Univ Nimes Hosp, Dept Med Oncol, Nimes, France

[15] Ramsay Hlth Grp Private Hosp Villeneuve dAscq, Dept Med Oncol, Villeneuve dAscq, France

[16] Pfizer Oncol, Lab Pfizer, Paris, France

[17] Merck Sante SAS, Lab Merck Sante, Lyon, France

[18] Univ Paris Saclay, Dept Canc Med, Gustave Roussy, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1835

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1757P

引用

页码：S1341 / S1342

页数：2